ARTICLE | Company News
Adimab grants Lilly rights to antibody discovery platform
August 4, 2017 7:50 PM UTC
Adimab LLC (Lebanon, N.H.) granted Eli Lilly and Co. (NYSE:LLY) exclusive rights to an antibody library and non-exclusive rights to Adimab’s antibody discovery platform in all therapeutic areas. Lilly will have an option to receive continued improvements to the Adimab platform, including access to new antibody libraries. ...